Status: Planned First registered on: 24/11/2021
Last updated on: 11/04/2023
1. Study identification
EU PAS Register NumberEUPAS32646
Official titleDulaglutide and Potential Risks of Pancreatic Cancer and Thyroid Cancer: A Non-Interventional PASS
Study title acronymH9X-MC-B013
Study typeObservational study
Brief description of the study
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? EU RMP category 3 (required)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsIQVIA
Department/Research group
Organisation/affiliationIQVIA
Website/Homepagehttps://www.iqvia.com/
Details of (Primary) lead investigator
Title Dr
Last name GPS Pharmacoepidemiology
First name Lilly
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
International study

Finland
Sweden
United States
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed07/11/2019
Start date of data collection31/03/2024
Start date of data analysis
Date of interim report, if expected
Date of final study report31/12/2030
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesEli Lilly & Co.100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name GPS Pharmacoepidemiology
First name Lilly
Address line 1Lilly Corporate Center
Address line 2 
Address line 3 
CityIndianapolis 
Postcode46285 
CountryUnited States
Phone number (incl. country code)3172762000 
Alternative phone number 
Fax number (incl. country code) 
Email address LillyGPSPE@lilly.com
Public Enquiries
Title Dr 
Last name GPS Pharmacoepidemiology 
First name Lilly 
Address line 1Lilly Corporate Center 
Address line 2 
Address line 3 
CityIndianapolis 
Postcode46285 
CountryUnited States 
Phone number (incl. country code)3172762000 
Alternative phone number 
Fax number (incl. country code) 
Email address LillyGPSPE@lilly.com 
Top